These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16918195)

  • 21. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carrier detection of deletions of the Hunter gene by in situ hybridization.
    Stone S; Adinolfi M
    Ann Hum Genet; 1992 May; 56(2):93-7. PubMed ID: 1503397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation analysis of iduronate-2-sulphatase gene in 24 patients with Hunter syndrome: characterisation of 6 novel mutations. Mutation in brief no. 249. Online.
    Hartog C; Fryer A; Upadhyaya M
    Hum Mutat; 1999; 14(1):87. PubMed ID: 10447264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene diagnosis and carrier detection in Hunter syndrome by the iduronate-2-sulphatase cDNA probe.
    Gal A; Beck M; Sewell AC; Morris CP; Schwinger E; Hopwood JJ
    J Inherit Metab Dis; 1992; 15(3):342-6. PubMed ID: 1357230
    [No Abstract]   [Full Text] [Related]  

  • 26. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iduronate sulfatase determination for the diagnosis of the Hunter syndrome and the detection of the carrier state.
    Neufeld EF; Liebaers I; Lim TW
    Adv Exp Med Biol; 1976; 68():253-60. PubMed ID: 820168
    [No Abstract]   [Full Text] [Related]  

  • 28. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
    Papadia F; Lozupone MS; Gaeta A; Capodiferro D; Lacalendola G
    Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):253-8. PubMed ID: 21528770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome).
    Garcia AR; Pan J; Lamsa JC; Muenzer J
    J Inherit Metab Dis; 2007 Nov; 30(6):924-34. PubMed ID: 17876721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Production of polyclonal antibodies to protein iduronate-2-sulphate sulphatase (IDS) and development of a detection system for human recombinant IDS].
    Peña O; Sosa A; Echeverri O; Sáenz H; Barrera LA
    Biomedica; 2005 Jun; 25(2):181-8. PubMed ID: 16022372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease).
    Voznyi YV; Keulemans JL; van Diggelen OP
    J Inherit Metab Dis; 2001 Nov; 24(6):675-80. PubMed ID: 11768586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene.
    Hopwood JJ; Bunge S; Morris CP; Wilson PJ; Steglich C; Beck M; Schwinger E; Gal A
    Hum Mutat; 1993; 2(6):435-42. PubMed ID: 8111411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mucopolysaccharidosis type II (Hunter syndrome)].
    Sukegawa K; Tomatsu S; Kondo N; Orii T
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):435-8. PubMed ID: 9645102
    [No Abstract]   [Full Text] [Related]  

  • 35. [Postnatal and prenatal diagnosis of mucopolysaccharidosis type II (Hunter syndrome)].
    Zhang WM; Shi HP; Li BT; Zhao SM; Qi QW; Sun NH; Huang SZ
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):644-7. PubMed ID: 17217652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iduronate sulfatase activity in serum, lymphocytes, and fibroblasts--simplified diagnosis of the Hunter syndrome.
    Liebaers I; Neufeld E
    Pediatr Res; 1976 Aug; 10(8):733-6. PubMed ID: 821034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The combination of recurrent otitis media and adenotomy in early childhood as diagnostic marker of mucopolysaccharidosis type II (Hunter syndrome)].
    Kuznetsova NE; Kuznetsova TB
    Vestn Otorinolaringol; 2022; 87(4):19-22. PubMed ID: 36107175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical practice guideline for the management of Hunter syndrome. Hunter España working group].
    Guillén-Navarro E; Blasco AJ; Gutierrez-Solana LG; Couce ML; Cancho-Candela R; Lázaro P;
    Med Clin (Barc); 2013 Nov; 141(10):453.e1-13. PubMed ID: 24060500
    [No Abstract]   [Full Text] [Related]  

  • 39. Characterization of dermatan sulfate and heparan sulfate in the urine of a patient with the Hunter syndrome.
    Kimura A; Hayashi S; Tsurumi K
    Tohoku J Exp Med; 1980 Jul; 131(3):227-39. PubMed ID: 6447930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.